Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer
Open accessAbstract
The T-box 3 (TBX3) transcription factor has been shown to serve multiple roles in normal development. Recent findings have revealed that TBX3 is overexpressed in different types of carcinomas, including breast, cervical, ovarian, melanoma, pancreatic, lung, liver, bladder, head and neck. Therefore, the present study investigated the significance of TBX3 as a diagnostic marker of breast cancer. To achieve this aim, breast cancer samples and their adjacent normal tissues were collected from 51 breast cancer patients from the European Gaza hospital during 2015-2016. Sections from each sample were immune-stained by anti-TBX3 and suitable secondary and tertiary antibodies. TBX3 levels were evaluated in cancerous and normal samples. Clinicopathological data for each patient were documented. The correlation between TBX3 levels and the clinicopathological parameters were statistically tested. The results revealed that TBX3 is significantly overexpressed in breast cancer tissues when compared with normal tissues. Furthermore, TBX3 was mainly a cytoplasmic protein in normal and breast cancer tissues. Notably, TBX3 levels exhibited a sensitivity of 78.4%, specificity of 79.6%, accuracy of 79% and area under the curve of 0.791 (0.700-0.882) at a cut-off value=9 as breast cancer marker. However, no significant associations were observed between TBX3 levels and other breast cancer markers including oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cancer antigen 15-3 and breast cancer stages. Altogether, these results suggested that TBX3 overexpression may be a potential biomarker for breast cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TBX3 behaves as a tumor suppressor or oncoprotein across cancer.
“TBX3 behaves as a tumor suppressor or oncoprotein across cancer.”
From Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma (2024) · cites this paper as [20]
The Introduction says TBX3 overexpression may drive cancer and describes its upregulation in melanoma and breast cancer. The Discussion also links TBX3 to oncogenic processes and lists other carcinomas. Neither passage says TBX3 acts as a tumor suppressor, so the claimed alternative role is unsupported. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The T-box transcription factor, TBX3, is sufficient to promote melanoma formation and invasion
Peres, J., & Prince, S. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-117 · Cited by 50 · see citing works
The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis
Peres, J., Mowla, S., & Prince, S. (2015) · Oncotarget · doi:10.18632/oncotarget.2782 · Cited by 40 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Cheng HD, Lui YM and Freimanis RI: A novel approach to microcalcification detection using fuzzy logic technique. IEEE Trans Med Imaging 17: 442-450, 1998.
- Sunwoo HH and Suresh MR: Cancer markers. In The Immunoassay. Handbook. Vol 1. 4th edition. Elsevier Ltd., Oxford, pp673-693, 2013.
Cited by
Sorted by citations
Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma
Deng, S., Lu, X., Wang, X., Liang, B., Xu, H., Yang, D., Cui, G., Yonemura, A., Paine, H., Zhou, Y., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06839-8 · Cited by 2 · see citing works
“Recent studies revealed TBX3 overexpression in diverse cancer types, which facilitates tumor development and progression [18 – 20].”
- Authors
- Aliwaini, S., Lubbad, A., Shourfa, A., Hamada, H., Ayesh, B., Abu Tayem, H., Abu Mustafa, A., Abu Rouk, F., Redwan, M., & Al‑Najjar, M.
- Affiliations
- Islamic University of Gaza (PS)
- Department of Oncology, European Gaza Hospital, 7049 Gaza, Palestine
- Dar Al-Shifa Hospital (PS)
- Al-Aqsa University (PS)
- Department of Biological Sciences and Biotechnology, Faculty of Sciences, Islamic University of Gaza, 108 Gaza, Palestine
- Nursing Department, Palestine College of Nursing, 7049 Gaza, Palestine
- Venue
- Molecular and Clinical Oncology
- Publisher
- Spandidos Publications
- Published
- 2018-11-09
- Volume
- 10
- Issue
- 1
- Pages
- 105-112
- ISSN
- 2049-9450 (ISSN-L)
- 2049-9469
- PMC
- PMC6313894
- OpenAlex
- W2900412765
- Cited by
- 13
- References
- 2
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 1
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Molecular and Clinical Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Islamic Development Bank
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- TBX3, breast cancer, transcription factor overexpression, diagnostic biomarkers, clinicopathological correlation, cytoplasmic protein localization, sensitivity and specificity, oestrogen receptor, progesterone receptor, HER2, CA15-3, tumor stage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review